ESTRO35 Programme Book

SCIENTIFIC PROGRAMME

| PROGRAMME AND EXHIBITION GUIDE

SATURDAY 30 APRIL 2016

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

09:35 > Future selection practice for proton therapy: selection of patients

based on treatment planning comparison and NTCP-modelling

Speaker: H. Langendijk (The Netherlands)

SP-0011

Symposium

MITIGATING NORMAL TISSUE TOXICITY

08:45 - 10:00 | LONDRA

The session is a well balanced session consisting of two biologically-oriented and experimental talks

(by S. van der Veen and L. Meziani) and one clinically oriented (by S. Delanian). The first talk will show

the benefit triggered by molecular modulation using ACE inhibitors on cardiopulmonary function and

cardiac damage. The second will review the clinical benefit of the combination Pentoxifyllin, Vitamin

E and Clodronate with possible mechanistic insights. The third will show the contribution of innate

immune system to late radiation-induced pulmonary damages with a specific focus on macrophages

leading to innovative therapeutic intervention.

Chair: M-C Vozenin (Switzerland)

Co-Chair: L. Pirtoli (Italy)

08:45 > The use of ACE inhibitors to attenuate thoracic irradiation-induced

cardiopulmonary toxicity.

Speaker: S. Van der Veen (The Netherlands)

SP-0012

09:10 > Radiation-induced musculosqueletic late damages: possible clinical

cure or simple mitigation?

Speaker: S. Delanian (France)

SP-0013

09:35 > Radiation-induced lung fibrosis is associated with M2 interstitial and

hybrid alveolar macrophages

Speaker: L. Meziani (France)

SP-0014

Symposium

REGIONAL NODAL IRRADIATION FOR BREAST CANCER

08:45 - 10:00 | AUDITORIUM

The first speaker in this session will review conflicting data around surgical and radiotherapeutic man-

agement of the axilla in breast cancer patients and how these impact on current clinical practice.

The second speaker will review recently published data on irradiation of the internal mammary chain

(IMC) with a view to determining whether every node-positive patient should have the IMC irradiated.

The final talk will cover technical approaches to treating locoregional lymph nodes and will review the

evidence base for dose constraints, the dosimetric consequences of different technical approaches

including protons, and the resource impact on our departments.

Chair: A. Kirby (UK)

Co-Chair: R. Orecchia (Italy)